Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

kelly smith

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

- PMLiVE

Envision appoints Jay Ferro as President, Technology and Chief Product Officer

Ferro was previously EVP, Chief Information, Technology & Product Officer at Clario

- PMLiVE

A simplified three-step process for achieving the fundamentals of omnichannel engagement in pharma: how to deliver impactful, connected experiences

By Aaron Fletcher

Amiculum

- PMLiVE

Grifols share results identifying early signs of Parkinson’s disease

Parkinson’s disease affects over six million people globally

- PMLiVE

Richmond Pharmacology appoints John Hotti as Chief Technology Officer

Hotti was previously Head of AI and CIO at Telrock Systems

- PMLiVE

Beyond the Linear Path: Leading with Your Full Self

Listen to the full episode here. In the latest episode of the Hear From Her podcast, Giulia Ghibellini (Teva Pharmaceuticals) and Professor Amanda Kirby (Do-IT Solutions) share how their experiences...

Medscape Education

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

- PMLiVE

Clasado appoints Sebastian Nummelin as new APAC Regional Director

Most recently Nummelin served as Director of APAC at TINE

Site Factor report illustrations

Why patient-centricity depends on site-centricity in clinical trials

Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.

Cuttsy + Cuttsy

- PMLiVE

Astellas’ application to EMA validated for treatment of muscle-invasive bladder cancer

Bladder cancer affects over 224,000 people annually in Europe, with over 30% of cases being muscle-invasive bladder cancer

- PMLiVE

CNX Therapeutics appoints David Flint as Chief Corporate Development Officer

Flint most recently held roles at UCB and Solvay

- PMLiVE

Potential US-Iran peace deal to redraw market winners and losers

With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links